alexa Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial

Marco Isaac Banda Lara1*, Martínez-García María del Carmen2, Vázquez-Rosales José Guillermo2, Rendón-Macías Mario Enrique2, Flores-Hernández Sergio3, Rivera-Benítez César1, Santos-González Margarito1 and Carrillo-Avalos Blanca4
1Servicio de Infectología, Hospital General de México. Eje 2A Sur (Dr. Balmis) #148, Col. Doctores, Del. Cuauhtémoc, CP 06726. Ciudad de México, D.F., México
2Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Av. Cuauhtémoc #330, Col Doctores, Del. Cuauhtémoc, C.P. 06720. Ciudad de México, D.F., México
3Instituto Nacional de Salud Pública. Universidad No. 655, Col. Santa María Ahuacatitlán, Cerrada los Pinos y Caminera, CP 62100. Cuernavaca, Morelos, México
4Facultad de Medicina, Universidad Autónoma de San Luis Potosi, México
Corresponding Author : Marco Isaac Banda Lara
Hospital General de Zona #2
San Luis Potosí. Benigno Arriaga esq Cuauhtémoc
Colonia Moderna, CP 78233, San Luis Potosí, San Luis Potosí, México
Tel: 52 4448120136
E-mail: [email protected]
Received: October 21, 2015 Accepted: November 10, 2015 Published: November 16, 2015
Citation: Lara MIB, Carmen MGMD, Guillermo VRJ, Enrique RMM, Sergio FH, et al. (2015) Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial. J Pharmacovigil 3:182. doi:10.4172/2329-6887.1000182
Copyright: © 2015 Lara MIB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Abstract

Background: The use of antiretroviral therapy (ART) reduces both mortality and morbidity of patients with HIV/ AIDS. The effects of chloroquine against HIV replication are widely known.

Objective: To demonstrate that beginning HIV treatment with ART (tenofovir/emtricitabine/efavirenz) + chloroquine increases by at least 20% the proportion of patients with viral load (VL) <50 copies/mL and >200 CD4+/mcL compared to patients receiving only ART at six months follow up.

Method: A randomized double-blind clinical trial was performed in 95 patients at the Infectious Diseases Department of the Hospital General de Mexico diagnosed with HIV/AIDS classification C3 before their first ART: 48 patients in the ART + placebo group and 47 in the ART + chloroquine group.

Results: A difference of 37% at six months of treatment in advantage of the group of ART + chloroquine (p<0.001), and seven times greater chance of improvement using chloroquine in the first six months of treatment. Chloroquine decreased the frequency of IRIS in 20%, compared with the group that initiated ART only at six months follow-up with statistical difference (p=0.029).

Conclusion: Chloroquine can improve the immune response and decrease the frequency of inflammatory syndrome by immune reconstitution at six months if added to the initial ART with tenofovir/emtricitabine/efavirenz.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords